Skip Navigation LinksTestOrderMycoTBDrugSusceptibility1st

microbial diseases laboratory branch

Test Name

Mycobacterium tuberculosis Complex: Drug Susceptibility Testing, First-Line



Test Methodology​

​Phenotypic drug susceptibility testing of Mycobacterium tuberculosis complex at critical concentrations by BACTEC MGIT 960 system.​​ Routinely tested drugs: isoniazid (INH) 0.1 μg/ml, rifampin (RIF) 1 µg/ml, pyrazinamide (PZA) 100 µg/ml, and ethambutol (EMB) 5 µg/ml. Submitters may request the alternative first-line DST panel where moxifloxacin (MFX) 0.25 µg/ml is tested instead of EMB. ā€‹ā€‹

​Reflex Testing
Criteria

​​​​If resistance to any of the first-line drugs (​except PZA) is detected, second-line drug susceptibility testing will be performed.

The default second-line drug panel includes amikacin (AMK), capreomycin (CAP), kanamycin (KAN), rifabutin (RFB), ethionamide (ETA), and MFX. If MFX testing was previously performed as part of alternative first-line DST and resistance to RIF, INH, or MFX was observed, EMB will be included in the second-line DST panel.

In addition, if resistance to INH at 0.1 μg/ml is detected, susceptibility testing to INH at 0.4 μg/ml will be performed.

Molecular detection of drug resistance by pyrosequencing may also be performed on cultures including mixed or contaminated cultures when there is known or suspected phenotypic drug resistance.

​Pre-Approval Required​
​​No, unless:
Duplicate submission, i.e., samples from the same patient collected within 3 months from prior collection date.

Supplemental Information and Required Form(s)​
Barcode submittal form 444 ā€œMycobacteriology-Drug Susceptibility Testing of MTBC (CA only)ā€  or instructions for using the MDL Lab Web Portal (ETOR) can be found at:  MDL Submission Instructions and Forms​.​​
​Indicate submitter’s test results on the submittal form.​​​
​Required Specimen Type(s)

​Pure culture ā€‹on solid or liquid media.
Slants (LJ/ 7H10) or liquid cultures (MGIT broth) are the preferred culture media for submission.

​Minimum Volume Required
​Viable growth should be present on subculture.
​​1.0 mL minimum if broth submitted

​Specimen Stability​

​​​Room Temp: up to 4 weeks.
Refrigerated (2 – 8°C): up to 6 months.
Frozen: Subculture prior to submission.
If culture age exceeds above mentioned, subculture prior to submission and submit fresh culture
​Rejection Criteria

  • ​​Samples with insufficient or conflicting labelling​​
  • ​Leaking samples
  • ​Isolates with no growth
  • ​Isolates that are nonviable
  • Mixed cultures
  • Specimen/sample types not meeting acceptance criteria​​
​Storage/Transport Conditions

​Grow isolate under appropriate conditions and verify purity prior to shipping. Isolates may be stored refrigerated or at ambient temperature prior to shipping.​

​Transport Medium,​
if applicable​​

​Not Applicable
​Specimen Labeling

​Two identifiers, including patient full name, and at least one other identifier (specimen accession number, date of birth, medical record number).​​
​Shipping Instructions and Specimen Handling Requirements

​​​Ship isolates at ambient temperature or with cold packs; do not freeze.

Follow the appropriate DOT/IATA approved shipping procedures. Suspected or confirmed MTBC cultures should be shipped as a Category A Infectious Substance, Affecting Humans (UN2814).

Ensure that culture isolates are sent in media flask or tubes containing a screw-top cap that is additionally sealed with parafilm or tape for additional protection against leaking. DO NOT send plate cultures.

Ship to:

California Department of Public Health​
Microbial Diseases Laboratory ​
ATTN:  TB Drug Susceptibility Testing Unit ā€‹ā€‹
850 Marina Bay Parkway, Specimen Receiving Room B106
Richmond, CA  94804

​Specimen Collection Instructions, if applicable

​​Not Applicable
​Turnaround Time


​17 days​
​Interferences & Limitations

​​Results may be delayed or unattainable if mixed culture is submitted.

​Reference Range
​Not Applicable​
​Additional Information
​​Isolates that are tested at MDL will be forwarded to the CDC if further characterization is needed or requested. 

​MDL Point of Contact
​For questions regarding submissions, please email  CDPHTBDST@cdph.ca.gov or call the MMPDS Section at (510) 412-3929​​

​

MDL ā€‹ā€‹Procedure Change​ Notification: Pyrazinamide (PZA) Drug Susceptibility Testing for TB​​
Page Last Updated :